Tag Archives: TMCx

RESI@TMCx Panel Announcement: Early Stage Therapeutic Investors

10 Mar

By Lucy Parkinson, Director of Research, LSN

Early stage therapeutics companies have a long road ahead to reach the marketplace, and will require significant investment along their way. The level of risk involved at this stage deters some investors, and much has been written about the pull-back of many venture capital firms from this phase of investment. At RESI, a panel of 5 investors who are highly experienced in investing in early stage therapeutic development will discuss how they pick winning scientfic teams and support their portfolio companies through the challenges of the development process.

Moderated by Lisa Rhoads, Managing Director, Easton Capital, the panel will feature:

This panel will give fundraising entrepreneurs a firsthand look at the strategies used by early stage therapeutic investors to assess companies at the earliest, riskiest stage of development, and will help the audience to position their companies as an attractive investment opportunity.

By registering for RESI@TMCx, you’ll be able to listen to the early stage therapeutic panel live in person, and also experience numerous opportunities to expand your network in the life sciences and to learn more about the fundraising process.

RESI-Houston-2016_600

RESI@TMCx Panel Announcement: Venture Philanthropy Investors

10 Mar

By Christine A. Wu, Research Analyst, LSN

chrsitine

Venture philanthropy organizations provide more than just financing. Often times, these investors can provide a network of experts, patients, and resources in their niche space. Here in Next Phase, LSN has previously covered trends in venture philanthropy investment and advice in how to approach venture philanthropy investors.

LSN is pleased to announce a panel of five investors in the venture philanthropy space for RESI@TMCx on April 11th. Moderated by Jit Patel, VP of Research and Business Development of Juvenile Diabetes Research Foundation (JDRF), the panel will be joined by:

Panelists will address their specific investment criteria and unique missions; their investment decision-making process; important trends in the space; and the best approach to reach and heighten their interest.

Interested in this panel? It’s not too late to register for RESI@TMCx Houston and see this panel live. View the full RESI@TMCx agenda here. You can also view a video recap of our RESI San Francisco Venture Philanthropy session.

RESI-Houston-2016_600

At RESI@TMCx, Make Your Fundraising Budget Count

3 Mar

By Nono Hu, Director of Marketing, LSN

What does it cost to raise capital? In LSN’s experience, one signal that consistently distinguishes a company that is committed to raising capital is that the company has a realistic plan and budget for their fundraising campaign. And when a company has a budget, it’s vital to ensure that they’re getting the most return on investment (ROI) possible from their campaign expenses.

That’s where the Redefining Early Stage Investments (RESI) Conference fits in. As a one-day event with a 1:1 ratio of investors to startup companies, RESI inundates attendees with opportunities to connect. Companies can book up to 16 face-to-face investor meetings in advance of the event; by providing so many opportunities to meet investors in one day, RESI is a high-value event for fundraising CEOs.

RESI Provides a Higher ROI for Cost Conscious CEOs

table
RESI-Houston-2016

RESI@TMCx: Agenda Announced

11 Feb

By Nono Hu, Director of Marketing, LSN

RESI is returning to TMCx on April 11th, and LSN has scheduled two all-day tracks of panel sessions that illuminate every corner of the life science investment landscape. Panels will feature senior, experienced investors from a diversity of investor types – including family offices, VCs, angel syndicates, major global pharma and medical device firms, and more. These investors will explore new investment trends in their sectors, and will share their knowledge and insights with RESI’s audience of entrepreneurs. If you’d like to join us at RESI@TMCx to hear the latest on life science financing and book one-on-one meetings with investors, you can register here.

RESI@TMCx Take 2: LSN, JLABS and TMCx Team-up Again for Early Stage Investor Event

21 Jan

By Michael Quigley, VP of Market Research, LSN

mike-2

On April 11th, Life Science Nation will be bringing together hundreds of senior level executives from investment firms, corporate strategics, and emerging biotech, medtech and digital health companies to the TMCx accelerator space at the Texas Medical Center in Houston. The recent RESI Conference in San Francisco had nearly 800 registrants and a full partnering floor. The event drew so much interest that registration was shut down a week prior to the event – and we received many regretful notes from those who wished they’d signed up sooner!

In addition to the firepower that LSN brings to the table, TMCx will be showcasing their second class of digital health and medical device technologies which will be announced later this month, and JLABS will be bringing senior executives from Johnson & Johnson and a number of entrepreneurs from the JLABS incubators.

RESI@TMCx will be a venue for entrepreneurs to meet with all 10 categories of investors LSN tracks including Family offices, Corporate Venture Funds, Angel Groups, Venture Philanthropy, Venture Capital and more. The RESI Partnering Forum will allow fundraising executives to identify and book up to 16 meetings with those diverse life science investors who fit their company’s technology sector and stage of development. Through an expansive series of investor panels, RESI @ TMCx will present current topics covering investment mandates and procedures for identifying and qualifying candidates. Additionally, RESI’s workshops will provide more in-depth advice on every aspect of the fundraising process.

 

RESI-Houston-2016_600

eb

RESI@TMCx: Innovators Are Invited To Apply

21 Jan

By Lucy Parkinson, Director of Research, LSN

Congratulations to Clearsight, Eve Medical, and Briteseed for their success in the RESI Innovation Challenge last week; at LSN, we hope that the success of these companies in RESI’s virtual fundraising challenge translates into real investor dollars!

If you’re interested in seeing your company’s name up there on the winner’s list, you can now apply to the RESI@TMCx Innovation Challenge for the conference on April 11, 2016. Successful applicants will be provided with a spot in the RESI Exhibitor Hall, and the challenge provides entrepreneurs with a way to engage with RESI’s audience of active life science investors throughout the event. All RESI attendees are provided with “RESI Cash” tokens that they can allocate to the entrepreneurs whose technologies they expect will be most successful. At the end of the day, the capital invested will be tallied up and the top 3 participants will be announced.

This exhibition-style, interaction-focused format was developed by LSN because we’ve found more traditional “pitch contests” to be of poor value for startups. If there are any active life science investors viewing a pitch session (and we’ve found that many investors just aren’t interested in this format), they don’t have a direct way to interact with the pitcher and offer their feedback. RESI therefore focuses on providing startups with the opportunity to meet investors face to face, both through one-on-one meetings and informal networking, and the RESI Innovation Challenge provides entrepreneurs with an eye-catching way to make those in-depth conversations happen.

Previous RESI Innovation Challenge winners include:

Clearsight (Aurora, CO)

Rna Diagnostics (Toronto, ON)

Redox (Madison, WI)

Empiriko (Newton, MA)

ORIG3N (Boston, MA)

Kineta (Seattle, WA)

If you’re developing a cutting-edge biotech or medtech product, apply to the RESI Innovation Challenge to put your technology into the spotlight. We’ll look forward to seeing you at RESI@TMCx.

%d bloggers like this: